Search Results - "Kiga, Yoko"

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM) by Niikura, Naoki, Yamanaka, Takashi, Nomura, Hironori, Shiraishi, Kazuhiro, Kusama, Hiroki, Yamamoto, Mitsugu, Matsuura, Kazuo, Inoue, Kenichi, Takahara, Sachiko, Kita, Shosuke, Yamaguchi, Miki, Aruga, Tomoyuki, Shibata, Nobuhiro, Shimomura, Akihiko, Ozaki, Yuri, Sakai, Shuji, Kiga, Yoko, Izutani, Tadahiro, Shiosakai, Kazuhito, Tsurutani, Junji

“…Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness…”
Get full text

Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of receptor activator of nuclear factor kappa B by Taguchi, Yuu, Kiga, Yoko, Gohda, Jin, Inoue, Jun-ichiro

“…Pathological bone resorption by osteoclasts is primarily treated with bisphosphonates. Because the administration of bisphosphonates is associated with a risk…”
Get full text

Abstract PD7-01: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: A multicenter retrospective study (ROSET-BM study) by Yamanaka, Takashi, Niikura, Naoki, Nomura, Hironori, Kusama, Hiroki, Yamamoto, Mitsugu, Matsuura, Kazuo, Inoue, Kenichi, Takahara, Sachiko, Kita, Shosuke, Yamaguchi, Miki, Aruga, Tomoyuki, Shibata, Nobuhiro, Shimomura, Akihiko, Ozaki, Yuri, Shiraishi, Kazuhiro, Sakai, Shuji, Kiga, Yoko, Izutani, Tadahiro, Shiosakai, Kazuhito, Tsurutani, Junji

“…Background: Brain metastases (BM) occur in 20%-50% of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC), and their presence is a poor…”
Get full text